Managing dialysis patients who develop anemia caused by chronic kidney disease: Focus on peginesatide

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3297-3307

  Valliant, Amanda ^a   Hofmann, R Michael ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Anemia; Chronic kidney disease; Peginesatide

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TRANSCRIPTION FACTOR GATA 2; TRANSFERRIN;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ANEMIA; ARTERY THROMBOSIS; ARTICLE; BLOOD TRANSFUSION; CELLULITIS; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; CONVULSION; DIET SUPPLEMENTATION; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FERRITIN BLOOD LEVEL; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; GENETIC TRANSCRIPTION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART ARRHYTHMIA; HEART INFARCTION; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERVOLEMIA; HYPOGLYCEMIA; INJECTION SITE REACTION; MEDICAID; MEDICARE; NEOPLASM; PATIENT CARE; PNEUMONIA; RESPIRATORY FAILURE; SEPSIS; TRANSFERRIN BLOOD LEVEL; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; URINARY TRACT INFECTION; VEIN THROMBOSIS;

ANEMIA; CHRONIC KIDNEY DISEASE; PEGINESATIDE;

ANEMIA; COMORBIDITY; EVIDENCE-BASED MEDICINE; HEMATINICS; HUMANS; PEPTIDES; PREVALENCE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84883178144     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S44944     Document Type: Article

References (49)

1. Foley R, Wang C, Collins A. Cardiovascular risk factor profiles and kidney function stage in the United States general population. The NHANES III study. Mayo Clinic Proc. 2005;80:1270-1277.
2. Krantz S. Erythropoietin. Blood Purif. 1991;77:419-434.
3. Bernhardt W, Wiesener M, Scigalla P, etal. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010;12:2151-2156.
4. Foley R, Parfrey P, Harnett J, Kent G, Murray D, Barre P. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. AmJ Kidney Dis. 1996;1:53-61.
5. Locatelli F, Aljama P, Barany P, etal. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(Suppl 2):1-47.
6. Besarab A. Treatment of Anemia in Dialysis Patients. 3rd ed. Baltimore, MD: Lippincott Williams & Wilkins; 2004.
7. Lemy A, Andrien M, Wissing K, etal. Major histocompatability complex class 1 chain-related antigen a antibodies: sensitizing events and impact on renal graft outcomes. Transplantation. 2010;90(2):168-174.
8. Lankhorst C, Wish J. Anemia in renal disease: diagnosis and management. Blood Rev. 2009;24:39-47.
9. Koury M, Bondurant M. The molecular mechanism of erythropoietin action. Eur J Biochem. 1992;201:649-663.
10. Macdougall I. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol. 2008;3:200-207.
11. Collins A, Li S, St. Peter W, etal. Death, hospitalization and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12:2465-2473.
12. Singh A, Szczech L, Tang K, etal. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.
13. Drueke T, Locatelli F, Clyne N, etal. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084.
14. Besarab A, Bolton W, Browne J, etal. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339: 584-590.
15. Strippoli G, Craig J, Manno C, Schena F. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol. 2004;12:3154-3165.
16. Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004;65(3):757-767.
17. Szczech L, Barnhart H, Inrig J, etal. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791-798.
18. KDOQI. NKF/KDOQI Clinical Practice Guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471-530.
19. Pfeffer M, Burdmann E, Chen C, etal. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361: 2019-2032.
20. Kapoian T, O'Mara N, Singh A, etal. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19:372-379.
21. Lawler E, Bradbury B, Fonda J, Gaziano J, Gagnon D. Transfusion burden among patients with chronic kidney disease and anemia. Clin J Am Soc Nephrol. 2010;5:667-672.
22. Spiegel D, Khan I, Krishan M, Mayne T. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008. Am J Kidney Dis. 2010;55:113-120.
23. National Kidney Foundation/Kidney Disease: Improving Global Outcomes. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int. 2012;2:279-331. http://www.kdigo.org/clinical_practice_guidelines/anemia.php.
24. National Institutes of Health. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: US Renal Data System; 2012.
25. Medicare program; end-stage renal disease prospective payment system, quality incentive program, and bad debt reductions for all Medicare providers: final rule. Centers for Medicare and Medicaid Services (CMS), HHS; 2012.
26. Saueressig U, Kwan J, De Cock E, Sapede C. Healthcare resource utilization for anemia management: current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly C.E.R.A. Blood Purif. 2008;26:537-546.
27. Chow K, Szeto C, Li P. Intravenous versus subcutaneous EPO: Anything to do with pure red cell aplasia complications. Am J Kidney Dis. 2003;41:266-267.
28. Katre N. Immunogenicity of recombinant IL-2modified by covalent attachment of polyethylene glycol. J Immunol. 1990;144:209-213.
29. Macdougall I. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis. 2012;59(3):444-451.
30. Schofield C, Ratcliffe P. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004;5:43-54.
31. Nangaku M, Kojima I, Tanaka T, Ohse T, Kato H, Fujita T. Novel drugs and the response to hypoxia: HIF stabilizers and prolyl hydroxylase. Recent Pat Cardiovasc Drug Discov. 2006;1:129-139.
32. Nangaku M, Eckardt K-U. Pathogenesis of renal anemia. Semin Nephrol. 2006;26:261-268.
33. La Ferla K, Reimann C, Jeikmann W, Hellwig-Burgel T. Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB. FASEB J. 2002;13:1811-1813.
34. Imagawa S, Nakano Y, Obara N, etal. A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB J. 2003;17(12):1742-1744.
35. Nakano Y, Imagawa S, Matsumoto K, etal. Oral administration of K-11706inhibitis GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood Purif. 2004;104(13):4300-4307.
36. Macdougall J, Malyszko J, Hider R, Bansal S. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(9):1681-1689.
37. Sasu B, Cooke K, Arvedson T, etal. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. 2010;115(17):3616-3624.
38. Wrighton N, Farrel F, Chang R, etal. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 1996;273(5274): 458-464.
39. Fan Q, Leuther K, Holmes C, etal. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol. 2006;10:1303-1311.
40. Woodburn K, Fan Q, Winslow S, etal. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol. 2007;35(8):1201-1208.
41. Stead R, Lambert J, Wessels D, etal. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006;108(6):1830-1834.
42. Macdougall I, Wiecek A, Tucker B, etal. Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol. 2011;6:2579-2586.
43. Macdougall I, Provenzano R, Sharma A, etal. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med. 2013;368:320-332.
44. Macdougall I, Rossert J, Casadevall N, etal. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361(19):1848-1855.
45. Locatelli F, Aljama P, Canaud B, etal. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant. 2010;9:2846-2850.
46. Yang B, Lum P, Hayashi M, Roskos L. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J Pharm Sci. 2004;93(5):1367-1373.
47. Garratty G. Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion. Vox Sang. 2008;94(2): 87-95.
48. Peginesatide (Omontys) for anemia in chronic kidney disease. Med Lett Drugs Ther. 2012;54(1392):45-46.
49. Fishbane SSB, Locatelli F, Covic AC, etal. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med. 2013;368:307-319.